Eli Lilly Reports Phase 2 Data for Tolebrutinib in ALS

Eli Lilly today announced Phase 2 results for Tolebrutinib in patients with ALS. The study demonstrated that Tolebrutinib reduces disease progression risk by over 40% compared to standard of care or placebo. These results provide important insights into the treatment of ALS and support the continued development of Tolebrutinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Tolebrutinib was consistent with previous observations, with no new safety signals identified.